Chimeric antigen receptor T-cell (or CAR-T) therapy and bispecific antibodies (BsAbs) have revolutionized the treatment of hematologic malignancies, offering new options for relapsed or refractory cases. However, these therapies carry risks of early complications, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and delayed issues like graft-versus-host disease (GVHD), infections, and secondary cancers. Effective management requires early diagnosis using advanced biomarkers and imaging, along with prompt interventions involving immunosuppressants, corticosteroids, and cytokine inhibitors. A multidisciplinary approach is essential, integrating hematologists, oncologists, and infectious disease specialists, with emerging strategies like targeted biologics and personalized medicine showing promise in balancing efficacy with toxicity management. Ongoing research is critical to refine diagnostics and treatments, ensuring that these therapies not only extend survival but also improve patients’ quality of life. This review provides critical insights for healthcare professionals to quickly recognize and treat complications of CAR-T and BsAbs therapies. By focusing on early detection through biomarkers and imaging and outlining timely therapeutic interventions, it aims to equip the multidisciplinary care team with the knowledge necessary to manage the challenges of these advanced treatments effectively, ultimately optimizing patient outcomes.

Myelomatous pleural effusion as an initial sign of multiple myeloma—a case report and review of literature

A qualitative study was conducted with 48 Chinese counselors and psychotherapists who were interviewed in 2006 and an independent sample of 50 participants who responded to a survey in 2014. This study aims to explore how the new emerging expansion of mental health practice is related to issues and challenges of dual role relationship and how the well-engrained values and social characteristics of Chinese culture influences perceptions and resolution of ethical dilemmas. The participants identified similar dual relationships in 2006 and 2014: (a) Incidental boundary crossings, a sexual or romantic relationship, a dual social relationship, and a professional dual relationship were the most frequently reported types of dual relationships encountered by Chinese practitioners, and (b) the socioeconomic and cultural context and the development trajectory of counseling and psychotherapy in China play a significant role in shaping practitioners’ behaviors. The comparison of the data in 2006 and 2014 indicated that practitioners in psychotherapy and counseling have an improved awareness and understanding of ethical issues, evidenced by the decreasing cases of romantic and sexual relationships and increasing cases of social dual relationships influenced by the interrelatedness of traditional Chinese culture.

Hemophilias and hemoglobinopathies—including hemophilias A and B, sickle cell disease (SCD), and β-thalassemia—are debilitating genetic disorders associated with significant global health burdens. While traditional management has centered on factor replacement and transfusions, these approaches remain palliative, with limited access and durability in many regions. Recent advances in immune-based therapeutics (e.g., emicizumab, concizumab, crizanlizumab), viral vector-mediated gene addition (e.g., Roctavian, Hemgenix), and gene-modified autologous stem cell therapies (e.g., Zynteglo, Casgevy) have ushered in a new era of disease-modifying and potentially curative interventions. These therapies offer durable efficacy and improved quality of life, particularly in adult populations. However, implementation remains uneven across global health systems due to high costs, limited infrastructure, and regulatory heterogeneity. Additionally, ethical considerations such as long-term surveillance, informed consent in vulnerable populations, and social perceptions of genetic modification present ongoing challenges. Innovations such as multiplex genome editing, immune-evasive donor platforms, synthetic biology, and AI-driven treatment modeling are poised to expand therapeutic horizons. Equitable access, particularly in regions bearing the highest disease burden, will require collaborative funding strategies, regional capacity building, and inclusive regulatory frameworks. This review summarizes the current landscape of curative therapy, outlines implementation barriers, and calls for coordinated international action to ensure that transformative care reaches all affected individuals worldwide.

肺肉瘤样癌（pulmonary sarcomatoid carcinoma, PSC）是一种罕见的肺部恶性肿瘤，属于非小细胞癌。但因其发病率低，目前治疗方法尚无定论。本研究旨在探讨PSC的临床特点、诊断标准、治疗方法及预后，为临床诊治提供一定依据。 回顾性分析2000年1月-2013年12月在我院治疗的38例肺肉瘤样癌患者的一般临床资料、吸烟史、临床表现、肿瘤大小、TNM分期、病理与免疫组化结果、诊断方法、治疗方法及预后。使用SPSS 19.0统计软件对结果进行分析，生存期使用Kaplan-Meier法进行分析。 本组患者年龄26岁-76岁（中位年龄57.5岁），男女比例约为4:1，81.6%的患者有长期大量吸烟史。咳嗽和咯血是最常见的首发症状。全部患者的中位生存期为21个月。1年、3年、5年累计生存率分别为68.4%、31.6%和18.4%。肿瘤大小、TNM分期、肿瘤是否发生远处转移及是否进行手术与患者的预后相关。 肺肉瘤样癌临床表现无特殊，影响肺肉瘤样癌预后的主要因素有：肿瘤大小、TNM分期、肿瘤是否发生远处转移及是否进行手术。目前，手术根治切除是治疗PSC的关键，其放化疗的综合治疗方式与配伍还需开展更多循证医学的探索。生物靶向药物可为PSC患者的治疗提供新的方向。